Reprint

The Molecular and Cellular Basis for Parkinson's Disease

Edited by
October 2019
230 pages
  • ISBN978-3-03921-548-5 (Paperback)
  • ISBN978-3-03921-549-2 (PDF)

This is a Reprint of the Special Issue The Molecular and Cellular Basis for Parkinson's Disease that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary
The focus on dopamine-sensitive motor symptoms, in association with the improvement of motor complications in the heterogeneous disease entity Parkinson's disease, has led to a certain standstill in research.<false,>This Special Issue provides new concepts and new ideas on the pathogenesis, genetics, and clinical maintenance of Parkinson's disease and related disorders. Not only new experimental findings, but also clinical outcomes, case series, and research on alternative, non-pharmacological therapies are included.<false,>The objective is to bridge the currently increasing gap between experimental and clinical research on Parkinson's disease and related disorders.
Format
  • Paperback
License and Copyright
© 2019 by the authors; CC BY-NC-ND license
Keywords
epigenetics; Parkinson’s disease; brain; DNA methylation; Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine; Parkinson’s disease; fatty acyls; glycerolipids; glycerophospholipids; sphingolipids; sterol lipids; lipoproteins; α-synuclein-mediated pathology; disease-modifying effects; neuroprotection; autophagy; cysteinyl-dopamine; hypochlorite; oxidative stress; Parkinson’s disease; redox cycling; Parkinson’s disease; brain iron; motor dysfunction; neurometabolites; magnetic resonance imaging; magnetic resonance spectroscopy; GABA; spectroscopy; Parkinson’s disease; neuroinflammation; alpha-Synuclein; immunotherapy; mesenchymal stem cells; secretome; exosomes; Parkinson’s disease; microRNAs; Parkinson disease; multiprofessional therapy; inpatient treatment; multimodal complex treatment; caffeic acid; chlorogenic acid; rotenone; Parkinson’s disease; neuroprotection; dopaminergic neuron; myenteric plexus; enteric glial cell; metallothionein; Parkinson’s disease; microbiota; molecular mimicry; microbiome; alpha-synuclein; curli; gut-brain axis; neurodegeneration; glucocerebrosidase; Parkinson’s disease; Gaucher’s disease; Lewy Body Dementia; REM sleep behavior disorders; [123I]FP-CIT-SPECT; DAT; nigral cells; Parkinson’s disease; parkinsonisms; cell line; differentiation; HOG; immature oligodendrocyte; Krabbe’s disease; oligodendrocyte; mature oligodendrocyte; MO3.13; myelin; multiple sclerosis; schizophrenia; SH-SY5Y